McKesson beats Q4 profit estimates, maintains long-term profit growth forecast

McKesson

07/05/2026 21:20

Overview

US healthcare distributor's fiscal Q4 revenue rose 6% yr/yr but missed analyst expectations

Adjusted EPS for fiscal Q4 rose 16% and beat analyst expectations

Company expanded share repurchase program, entering $2.25 bln accelerated buyback

Outlook

McKesson sees fiscal 2027 adjusted EPS between $43.80 and $44.60

Company reaffirms long-term adjusted EPS growth target of 13% to 16%

McKesson targets long-term segment operating profit growth of 5%-8% for North American Pharmaceutical, 13%-16% for Oncology & Multispecialty, 10%-13% for Prescription Technology Solutions

Result Drivers

ONCOLOGY & SPECIALTY GROWTH - Q4 revenue growth was driven by increased distribution of oncology and multispecialty products, including contributions from acquisitions

HIGHER PRESCRIPTION VOLUMES - Growth in the North American Pharmaceutical segment was due to increased prescription transaction volumes, partially offset by lower contributions from branded pharmaceuticals

ADJUSTED EPS DRIVERS - Adjusted EPS growth was driven by operational growth, acquisitions in Oncology & Multispecialty, a lower share count, and a lower tax rate

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$96.30 bln
$101.35 bln (14 Analysts)
Q4 Adjusted EPS
Beat
$11.69
$11.56 (16 Analysts)
Q4 EPS
$13.71
Q4 Adjusted Net Income
Meet
$1.43 bln
$1.43 bln (13 Analysts)

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)